Andrew Lees Email

CEO and Owner . Fina BioSolutions

Current Roles

Employees:
10
Revenue:
$1.6M
About
Fina Biosolutions LLC is a privately held research and development stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for prevention of life-threatening diseases. Fina has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorixâ„¢ Menitorixâ„¢, Nimenrixâ„¢, The Serum Institute of India Ltd., The Chengdu Institute of Biological Products and others. Fina Bosolutions also manufactures E. coli expressed CRM197 conjugate vaccine carrier portein. Fina BioSolutions also develops polymer based diagnostic reagents, amino dextran, and antibody dextran conjugates.
Fina BioSolutions Address
9430 Key West Ave suite 200
Rockville, MD
United States
Fina BioSolutions Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.